secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-294936
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Phase 2b MM-120 in GAD meets primary endpoint, 7.6-point HAM-A improvement vs placebo
--------------------------------------------------------------------------------

- MM-120 100 µg achieved 21.3-point HAM-A reduction vs 13.7 placebo (p=0.0004, Cohen's d=0.88) at Week 4 after single dose.
- Clinical response rate 78% (100/200 µg) and remission 50% (100 µg) at Week 4; CGI-S improved from 'markedly ill' to 'borderline'.
- Well-tolerated with mostly mild-moderate AEs on dosing day; 97.5% completion in high-dose groups with no AE discontinuations.
- Plans End-of-Phase 2 meeting with FDA in H1 2024 and initiation of Phase 3 program in H2 2024; 12-week data expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312523294936/0001193125-23-294936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312523294936/d605082d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-294936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer